Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas
暂无分享,去创建一个
Christian Woiciechowsky | Holger Amthauer | H. Amthauer | C. Woiciechowsky | M. Plotkin | Frank K.H. Landeghem | Michail Plotkin | F. Stockhammer | Florian Stockhammer | Frank K. H. van Landeghem
[1] J. Saver,et al. A Quantitative Study , 2005 .
[2] H. Nawashiro,et al. L‐type amino acid transporter 1 as a potential molecular target in human astrocytic tumors , 2006, International journal of cancer.
[3] L D Lunsford,et al. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. , 1993, Journal of neurosurgery.
[4] W. Koch,et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] Karl-Josef Langen,et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. , 2006, Nuclear medicine and biology.
[6] W. Paulus,et al. Intratumoral histologic heterogeneity of gliomas. A quantitative study , 1989, Cancer.
[7] Wolfgang A. Weber,et al. O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study , 2000, European Journal of Nuclear Medicine.
[8] Karl Herholz,et al. Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[9] C. Götz,et al. Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[10] G. Fuller,et al. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. , 1998, Surgical neurology.
[11] Karl-Josef Langen,et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.
[12] J. M. Ollinger,et al. Positron Emission Tomography , 2018, Handbook of Small Animal Imaging.
[13] H. Engler,et al. Positron emission tomography 11C‐methionine and survival in patients with low‐grade gliomas , 2001 .
[14] R. Goldbrunner,et al. O-(2-[18F]fluoroethyl)-l-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[15] H. Engler,et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. , 2001, Cancer.
[16] A. Thiel,et al. 11C-methionine PET for differential diagnosis of low-grade gliomas , 1998, Neurology.
[17] T. Hölzer,et al. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using f-18-fluorodeoxyglucose and c-11-L-methylmethionine. , 1997, Neurosurgery.
[18] S. Stiver. Angiogenesis and its role in the behavior of astrocytic brain tumors. , 2004, Frontiers in bioscience : a journal and virtual library.
[19] Jörg-Christian Tonn,et al. Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[20] K. Plate,et al. Angiogenesis in malignant gliomas , 1995, Glia.
[21] I. Fichtner,et al. The Thalidomide Analogue, CC-4047, Induces Apoptosis Signaling and Growth Arrest in Childhood Acute Lymphoblastic Leukemia Cells In vitro and In vivo , 2006, Clinical Cancer Research.
[22] F Shishido,et al. Cerebral glioma: evaluation with methionine PET. , 1993, Radiology.
[23] G. Reifenberger,et al. Prognostic Value of O-(2-18F-Fluoroethyl)-l-Tyrosine PET and MRI in Low-Grade Glioma , 2007, Journal of Nuclear Medicine.
[24] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[25] K. Hamacher,et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[26] C. Marras,et al. CXCL12 Expression is Predictive of a Shorter Time to Tumor Progression in Low-Grade Glioma: A Single-Institution Study in 50 Patients , 2005, Journal of Neuro-Oncology.
[27] W. Remmele,et al. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer , 2004, Virchows Archiv A.
[28] O. Witte,et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. , 2001, Journal of neurosurgery.
[29] Hong Wang,et al. Platelet‐derived growth factor stimulates LAT1 gene expression in vascular smooth muscle: Role in cell growth , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] Alexander Muacevic,et al. Accuracy and clinical applicability of a passive marker based frameless neuronavigation system , 2000, Journal of Clinical Neuroscience.
[31] S. Coca,et al. Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendrogliomas. , 2000, Surgical neurology.
[32] J. Rock,et al. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. , 1998, Journal of neurosurgery.
[33] B. Weber,et al. Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 Gliomas and Correlation with 131I-SIP(L19), a Marker of Angiogenesis , 2007, Journal of Nuclear Medicine.
[34] W. K. Alfred Yung. PATHOLOGY AND GENETICS OF TUMOURS OF THE NERVOUS SYSTEM , 2002 .
[35] P. Courtheoux,et al. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. , 1997, Neurosurgery.
[36] Susan M. Chang,et al. Age and the risk of anaplasia in magnetic resonance‐nonenhancing supratentorial cerebral tumors , 1997, Cancer.